Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Fluconazole in vitro susceptibility test results for 256,882 isolates of Candida spp. were collected from 142 sites in 41 countries from June 1997 to December 2007. Data were collected for 197,619 isolates tested with voriconazole from 2001 to 2007. A total of 31 different species of Candida were isolated. Increased rates of isolation of the common non- albicans species C. glabrata (10.2% to 11.7%), C. tropicalis (5.4% to 8.0%), and C. parapsilosis (4.8% to 5.6%) were noted when the time periods 1997 to 2000 and 2005 to 2007 were compared. Investigators tested clinical isolates of Candida spp. by the CLSI M44-A disk diffusion method. Overall, 90.2% of Candida isolates tested were susceptible (S) to fluconazole; however, 13 of 31 species identified exhibited decreased susceptibility (<75% S), similar to that seen with the resistant (R) species C. glabrata and C. krusei . Among 197,619 isolates of Candida spp. tested against voriconazole, 95.0% were S and 3% were R. About 30% of fluconazole-R isolates of C. albicans , C. glabrata , C. tropicalis , C. rugosa , C. lipolytica , C. pelliculosa , C. apicola , C. haemulonii , C. humicola , C. lambica , and C. ciferrii remained S to voriconazole. An increase in fluconazole resistance over time was seen with C. parapsilosis , C. guilliermondii , C. lusitaniae , C. sake , and C. pelliculosa . Among the emerging fluconazole-R species were C. guilliermondii (11.4% R), C. inconspicua (53.2% R), C. rugosa (41.8% R), and C. norvegensis (40.7% R). The rates of isolation of C. rugosa , C. inconspicua , and C. norvegensis increased by 5- to 10-fold over the 10.5-year study period. C. guilliermondii and C. rugosa were most prominent in Latin America, whereas C. inconspicua and C. norvegensis were most common in Eastern European countries. This survey identifies several less-common species of Candida with decreased susceptibility to azoles. These organisms may pose a future threat to optimal antifungal therapy and underscore the importance of prompt and accurate species identification and antifungal susceptibility testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The actual proportion of C. albicans is well over 50–70% in Northern and Middle Europe, while mostly well below 50% in Southern Europe, Latin America, Australia, and the US.59,60”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [60]
In the citing paper
“For example, an increase in fluconazole resistance in naturally susceptible species such as C. parapsilosis, C. guilliermondii, C. lusitaniae, C. sake, and C. pelliculosa was observed in a population-based surveillance programme comprising more than 250,000 Candida strains isolated between 1997 and 2007 [43].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [43]
In the citing paper
“With respect to CLSI clinical breakpoints, fluconazole resistance, defined as MIC values ≥8 mg/L for C. albicans, has been reported overall to be as high as 3.5%.43–48”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [43]
In the citing paper
“About 1.4% of C. albicans isolates were resistant to fluconazole, of which 63.6% were cross-resistant to voriconazole.43”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [43]
Citations
Cites
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“glabrata to develop resistance to both triazoles (2, 10, 12, 17, 27, 46, 55, 63).”
BackgroundSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 3×
“These and other relatively rare species of Candida are unlikely to be familiar to many clinicians and microbiologists, and there are few or no data concerning prognosis or optimal treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66).”
BackgroundReference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Candida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854 · cited 4×
“(69), and it is evident that when lapses in infection control”
BackgroundInfluentialPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694
Self-citationParczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656
New and emerging yeast pathogens
Hazen, K. C. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.462 · Cited by 614 · cited 1×
“ods, and the remainder used the classical methods alone (19, 21).”
MethodNucci, M., & Marr, K. A. (2005) · Clinical Infectious Diseases · doi:10.1086/432060 · Cited by 435 · cited 2×
“These and other relatively rare species of Candida are unlikely to be familiar to many clinicians and microbiologists, and there are few or no data concerning prognosis or optimal treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66).”
BackgroundPfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423 · cited 1×
“glabrata to develop resistance to both triazoles (2, 10, 12, 17, 27, 46, 55, 63).”
BackgroundSelf-citationMethod for antifungal disk diffusion susceptibility testing of yeasts : Approved guideline
Rex, J. H., & Clinical (2009) · Clinical and Laboratory Standards Institute eBooks · Cited by 422
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01747-08 · Cited by 370
Self-citationCandidaemia in Europe: epidemiology and resistance
TORTORANO, A., KIBBLER, C., PEMAN, J., BERNHARDT, H., KLINGSPOR, L., & GRILLOT, R. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.01.002 · Cited by 352 · cited 1×
“Global surveillance programs such as the ARTEMIS antifungal surveillance program for DD testing (49, 57, 60) and MIC testing (12, 13), the European Confederation of Medical Mycology (ECMM) survey of candidemia (68), and the SENTRY Antifungal Surveillance Program (36–38) promote the use of standardized DD and BMD metho…”
MethodHachem, R., Hanna, H., Kontoyiannis, D., Jiang, Y., & Raad, I. (2008) · Cancer · doi:10.1002/cncr.23466 · Cited by 331 · cited 1×
“norvegensis according to clinical service (3, 11, 18, 58, 62).”
BackgroundPfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 295 · cited 10×
“Disk diffusion (DD) testing of fluconazole and voriconazole was performed as described previously (20, 57) and in CLSI document M44-A (7).”
BackgroundInfluentialSelf-citationPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Meis, J. F., Gould, I. M., Fu, W., Colombo, A. L., & Rodriguez-Noriega, E. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00409-07 · Cited by 284
Self-citationPfaller, M. A., & Diekema, D. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3551-3557.2002 · Cited by 269 · cited 1×
“The ARTEMIS global antifungal surveillance program is among the most comprehensive and long-running fungal surveillance programs (12, 45, 57, 58, 60).”
BackgroundSelf-citationPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Nagy, E., Dobiasova, S., Rinaldi, M., Barton, R., Veselov, A., & the Global Antifungal Surveillance Group (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01915-07 · Cited by 259
Self-citationPfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258 · cited 10×
“Disk diffusion (DD) testing of fluconazole and voriconazole was performed as described previously (20, 57) and in CLSI document M44-A (7).”
BackgroundInfluentialSelf-citationCurrent Treatment Strategies for Disseminated Candidiasis
Spellberg, B. J., Filler, S. G., & Edwards, J. E. (2006) · Clinical Infectious Diseases · doi:10.1086/499057 · Cited by 256 · cited 3×
“These and other relatively rare species of Candida are unlikely to be familiar to many clinicians and microbiologists, and there are few or no data concerning prognosis or optimal treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66).”
BackgroundCandida, Cryptococcus, and Other Yeasts of Medical Importance
Howell, S. A., & Hazen, K. C. (2011) · Manual of Clinical Microbiology · doi:10.1128/9781555816728.ch115 · Cited by 246
Pfaller, M. A., Diekema, D. J., Rinaldi, M. G., Barnes, R., Hu, B., Veselov, A. V., Tiraboschi, N., Nagy, E., & Gibbs, D. L. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.12.5848-5859.2005 · Cited by 228
Self-citationLockhart, S. R., Messer, S. A., Pfaller, M. A., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00803-08 · Cited by 206
Self-citationClark, T. A., Slavinski, S. A., Morgan, J., Lott, T., Arthington-Skaggs, B. A., Brandt, M. E., Webb, R. M., Currier, M., Flowers, R. H., Fridkin, S. K., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4468-4472.2004 · Cited by 200
Pfaller, M. A., Diekema, D. J., Mendez, M., Kibbler, C., Erzsebet, P., Chang, S.-C., Gibbs, D. L., Newell, V. A., & the Global Antifungal Surveillance Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00865-06 · Cited by 194
Self-citationSarvikivi, E., Lyytikäinen, O., Soll, D. R., Pujol, C., Pfaller, M. A., Richardson, M., Koukila-Kähkölä, P., Luukkainen, P., & Saxén, H. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.6.2729-2735.2005 · Cited by 178
Self-citationCandidemia in Norway (1991 to 2003): Results from a Nationwide Study
Sandven, P., Bevanger, L., Digranes, A., Haukland, H. H., Mannsåker, T., Gaustad, P., & the Norwegian Yeast Study Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00029-06 · Cited by 173
Messer, S. A., Jones, R. N., & Fritsche, T. R. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.5.1782-1787.2006 · Cited by 172
Epidemiology of Candidemia in a Tertiary Care Centre of North India: 5-Year Study
Xess, I., Jain, N., Hasan, M. F., Mandal, P., & Banerjee, U. (2007) · Infection · doi:10.1007/s15010-007-6144-6 · Cited by 170
Spanakis, E. K., Aperis, G., & Mylonakis, E. (2006) · Clinical Infectious Diseases · doi:10.1086/507891 · Cited by 167 · cited 4×
“These and other relatively rare species of Candida are unlikely to be familiar to many clinicians and microbiologists, and there are few or no data concerning prognosis or optimal treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66).”
InfluentialClinical Significance of Azole Antifungal Drug Cross-Resistance in Candida glabrata
Panackal, A. A., Gribskov, J. L., Staab, J. F., Kirby, K. A., Rinaldi, M., & Marr, K. A. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.5.1740-1743.2006 · Cited by 144 · cited 2×
“causing infection in patients with previous fluconazole exposure are very likely to show decreased susceptibility to voriconazole as well (1, 32, 42).”
BackgroundMagill, S. S., Shields, C., Sears, C. L., Choti, M., & Merz, W. G. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.529-535.2006 · Cited by 139 · cited 2×
“causing infection in patients with previous fluconazole exposure are very likely to show decreased susceptibility to voriconazole as well (1, 32, 42).”
BackgroundArendrup, M. C., Fuursted, K., Gahrn-Hansen, B., Schønheyder, H. C., Knudsen, J. D., Jensen, I., Bruun, B., Christensen, J. J., & Johansen, H. K. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01954.x · Cited by 134 · cited 1×
“glabrata to develop resistance to both triazoles (2, 10, 12, 17, 27, 46, 55, 63).”
BackgroundCuenca-Estrella, M., Rodriguez, D., Almirante, B., Morgan, J., Planes, A. M., Almela, M., Mensa, J., Sanchez, F., Ayats, J., Gimenez, M., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh548 · Cited by 132
Invasive Candida species infections: a 5 year population-based assessment
Laupland, K. B., Gregson, D. B., Church, D. L., Ross, T., & Elsayed, S. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki258 · Cited by 130 · cited 2×
“glabrata to develop resistance to both triazoles (2, 10, 12, 17, 27, 46, 55, 63).”
BackgroundDiekema, D. J., Messer, S. A., Boyken, L. B., Hollis, R. J., Kroeger, J., Tendolkar, S., & Pfaller, M. A. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00942-09 · Cited by 125 · cited 2×
“These and other relatively rare species of Candida are unlikely to be familiar to many clinicians and microbiologists, and there are few or no data concerning prognosis or optimal treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66).”
BackgroundMethodSelf-citationGonzález, G. M., Elizondo, M., & Ayala, J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-08 · Cited by 122 · cited 1×
“glabrata to develop resistance to both triazoles (2, 10, 12, 17, 27, 46, 55, 63).”
BackgroundYang, Y.-L., Ho, Y.-A., Cheng, H.-H., Ho, M., & Lo, H.-J. (2004) · Infection Control & Hospital Epidemiology · doi:10.1086/502294 · Cited by 119 · cited 2×
“tropicalis from the Asia-Pacific region (Table 7) (71, 74).”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ng, K. P., Colombo, A., Finquelievich, J., Barnes, R., & Wadula, J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02122-07 · Cited by 108
Self-citationHsueh, P.-R., Lau, Y.-J., Chuang, Y.-C., Wan, J.-H., Huang, W.-K., Shyr, J.-M., Yan, J.-J., Yu, K.-W., Wu, J.-J., Ko, W.-C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.512-517.2005 · Cited by 105
Gales, A. C., Pfaller, M. A., Houston, A. K., Joly, S., Sullivan, D. J., Coleman, D. C., & Soll, D. R. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.12.3804-3808.1999 · Cited by 103
Self-citationPfaller, M. A., Diekema, D. J., Colombo, A. L., Kibbler, C., Ng, K. P., Gibbs, D. L., Newell, V. A., & the Global Antifungal Surveillance Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00863-06 · Cited by 99
Self-citationLockhart, S. R., Messer, S. A., Gherna, M., Bishop, J. A., Merz, W. G., Pfaller, M. A., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.02315-08 · Cited by 99
Self-citationHazen, K. C., Baron, E. J., Colombo, A. L., Girmenia, C., Sanchez-Sousa, A., del Palacio, A., de Bedout, C., & Gibbs, D. L. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5623-5632.2003 · Cited by 98
Self-citationGenetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei
Fukuoka, T., Johnston, D. A., Winslow, C. A., de Groot, M. J., Burt, C., Hitchcock, C. A., & Filler, S. G. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1213-1219.2003 · Cited by 96 · cited 1×
“krusei, is well known, and studies have demonstrated that the voriconazole activity against this species may be attributed to enhanced binding of this triazole to the target enzyme compared to that of fluconazole (15, 56, 58).”
ResultPfaller, M. A., Boyken, L., Messer, S. A., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5208-5213.2005 · Cited by 89 · cited 1×
“The ARTEMIS program was designed to address many of the potential limitations of resistance surveillance studies (26): (i) it is both longitudinal (1997 to present) and global (142 participating sites in 41 countries) in scope, (ii) it employs standardized DD (7) and BMD (9) antifungal susceptibility test methods, (ii…”
MethodSelf-citationCandida glabrata Fungemia in Transplant Patients Receiving Voriconazole after Fluconazole
Alexander, B. D., Schell, W. A., Miller, J. L., Long, G. D., & Perfect, J. R. (2005) · Transplantation · doi:10.1097/01.tp.0000173771.47698.7b · Cited by 78 · cited 2×
“causing infection in patients with previous fluconazole exposure are very likely to show decreased susceptibility to voriconazole as well (1, 32, 42).”
BackgroundMesser, S. A., Moet, G. J., Kirby, J. T., & Jones, R. N. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.02434-08 · Cited by 75 · cited 1×
“Meaningful large-scale surveys of antifungal susceptibility and resistance conducted over time would not be possible without a standardized broth microdilution (BMD) or disk diffusion (DD) method for performing the in vitro studies (12, 38, 60).”
MethodYang, Y.-L., Wang, A.-H., Wang, C., Cheng, W.-T., Li, S., & Lo, H. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.01.011 · Cited by 73
Chen, A., & Sobel, J. D. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.21 · Cited by 59 · cited 1×
“Given the ubiquitous use of azoles in prophylaxis and empirical and directed therapies (4, 43, 65, 66), it is important to know the activities of the systemically active agents, such as fluconazole and voriconazole, against these organisms (65, 66).”
BackgroundSusceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002
Yang, Y.-L., Li, S.-Y., Cheng, H.-H., & Lo, H. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.11.004 · Cited by 57
Rare and emerging Candida species
Johnson, E. M. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0020-z · Cited by 57 · cited 2×
“These and other relatively rare species of Candida are unlikely to be familiar to many clinicians and microbiologists, and there are few or no data concerning prognosis or optimal treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66).”
BackgroundPfaller, M. A., Hazen, K. C., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.8.3607-3612.2004 · Cited by 55 · cited 1×
“The ARTEMIS program was designed to address many of the potential limitations of resistance surveillance studies (26): (i) it is both longitudinal (1997 to present) and global (142 participating sites in 41 countries) in scope, (ii) it employs standardized DD (7) and BMD (9) antifungal susceptibility test methods, (ii…”
MethodSelf-citationInitial results from a longitudinal international surveillance programme for anidulafungin (2003)
Messer, S. A., Kirby, J. T., Sader, H. S., Fritsche, T. R., & Jones, R. N. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh504 · Cited by 52
Lee, J.-S., Shin, J. H., Lee, K., Kim, M.-N., Shin, B.-M., Uh, Y., Lee, W.-G., Lee, H. S., Chang, C. L., Kim, S. H., et al. (2007) · Yonsei Medical Journal · doi:10.3349/ymj.2007.48.5.779 · Cited by 51
Johnson, E. M., Espinel‐Ingroff, A., Székely, A., Hockey, H. P., & Troke, P. F. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.05.023 · Cited by 50 · cited 1×
“parapsilosis to both fluconazole and voriconazole (24, 55).”
BackgroundResistance surveillance studies--comparability of results and quality assurance of methods
Kahlmeter, G., & Brown, D. F. J. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg041 · Cited by 48 · cited 1×
“The ARTEMIS program was designed to address many of the potential limitations of resistance surveillance studies (26): (i) it is both longitudinal (1997 to present) and global (142 participating sites in 41 countries) in scope, (ii) it employs standardized DD (7) and BMD (9) antifungal susceptibility test methods, (ii…”
MethodLockhart, S. R., Messer, S. A., Pfaller, M. A., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01889-08 · Cited by 41
Self-citationCandida norvegensis: a fluconazole-resistant species
Sandven, P., Nilsen, K., Digranes, A., Tjade, T., & Lassen, J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1375 · Cited by 41 · cited 7×
“krusei, are often seen as colonizers (3, 22, 58, 62), isolates from blood and NSBF are reported in this survey (Table 9) and in other reports in the literature (3, 11, 34, 35, 39, 40, 62).”
BackgroundResultInfluentialMajoros, L., Kardos, G., Belák, Á., Maráz, A., Asztalos, L., Csánky, E., Barta, Z., & Szabó, B. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.11.5250-5253.2003 · Cited by 40 · cited 3×
“Those strains from services with only a few isolates and those for which a clinical service was not specified were included in the category “other, not otherwise specified” (other, NOS).”
InfluentialA Nosocomial Cluster of Candida inconspicua Infections in Patients with Hematological Malignancies
D’Antonio, D., Violante, B., Mazzoni, A., Bonfini, T., Capuani, M. A., D’Aloia, F., Iacone, A., Schioppa, F., & Romano, F. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.3.792-795.1998 · Cited by 37 · cited 9×
“Skin/soft tissue (11,221) Fluconazole 252 81.”
BackgroundResultInfluentialNielsen, H. S., Stenderup, J., Bruun, B., & Ladefoged, J. (1990) · Journal of Clinical Microbiology · doi:10.1128/jcm.28.7.1664-1665.1990 · Cited by 34
Baily, G. G., Moore, C. B., Essayag, S. M., de Wit, S., Burnie, J. P., & Denning, D. W. (1997) · Clinical Infectious Diseases · doi:10.1086/516894 · Cited by 34 · cited 5×
“krusei, are often seen as colonizers (3, 22, 58, 62), isolates from blood and NSBF are reported in this survey (Table 9) and in other reports in the literature (3, 11, 34, 35, 39, 40, 62).”
BackgroundResultInfluentialPfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.05.007 · Cited by 34
Self-citationSugita, T., Takeo, K., Ohkusu, M., Virtudazo, E. V., Takashima, M., Asako, E., Ohshima, F., Harada, S., Yanaka, C., Nishikawa, A., et al. (2004) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2004.tb03602.x · Cited by 33
Yang, Y.-L., Cheng, H.-H., & Lo, H. (2006) · Medical Mycology · doi:10.1080/13693780500401213 · Cited by 32
A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
Diekema, D. J., Messer, S. A., Hollis, R. J., Boyken, L. B., Tendolkar, S., Kroeger, J. S., Jones, R. N., & Pfaller, M. A. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.11.001 · Cited by 26 · cited 4×
“glabrata to develop resistance to both triazoles (2, 10, 12, 17, 27, 46, 55, 63).”
BackgroundMethodInfluentialSelf-citationEpidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan.
Chen, T., Chen, Y., Tsai, J., Peng, C., Lu, P., Chang, K., Hsieh, H., & Chen, T. (2005) · PubMed · Cited by 25
Isolation of Candida norvegensis from Clinical Specimens: Four Case Reports
Hood, S., Moore, C. B., & Denning, D. W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.5.1185 · Cited by 19 · cited 2×
“krusei, are often seen as colonizers (3, 22, 58, 62), isolates from blood and NSBF are reported in this survey (Table 9) and in other reports in the literature (3, 11, 34, 35, 39, 40, 62).”
BackgroundResultInvasive Candida norvegensis Infection in Immunocompromised Patients
Nielsen, H., & Stenderup, J. (1996) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549609027180 · Cited by 18 · cited 2×
“krusei, are often seen as colonizers (3, 22, 58, 62), isolates from blood and NSBF are reported in this survey (Table 9) and in other reports in the literature (3, 11, 34, 35, 39, 40, 62).”
BackgroundResultNational surveillance of antifungal susceptibility ofCandidaspecies in South Korean hospitals
Yoo, J. I., Choi, C. W., Lee, K. M., Kim, Y. K., Kim, T. U., Kim, E.-C., Joo, S. I., Yun, S. H., Lee, Y. S., & Kim, B. S. (2008) · Medical Mycology · doi:10.1080/13693780802354037 · Cited by 18
Majoros, L., Kardos, G., Szabó, B., Kovács, M., & Maráz, A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh539 · Cited by 13
New developments in the antifungal susceptibility testing of Candida
Pfaller, M. A. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0019-x · Cited by 10 · cited 2×
“APAC (44,674) EU (109,643) AF/ME (8,259) LAM (27,395) NAM (11,682) Total (201,653)”
Self-citationIn vitro activity of caspofungin and voriconazole against uncommon Candida spp.
Angoulvant, A., Girard, A., POIROT, J. L., & Hennequin, C. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.12.002 · Cited by 9 · cited 3×
“These and other relatively rare species of Candida are unlikely to be familiar to many clinicians and microbiologists, and there are few or no data concerning prognosis or optimal treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66).”
BackgroundMajoros, L., Kardos, G., Feiszt, P., & Szabó, B. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki174 · Cited by 8 · cited 2×
“krusei, are often seen as colonizers (3, 22, 58, 62), isolates from blood and NSBF are reported in this survey (Table 9) and in other reports in the literature (3, 11, 34, 35, 39, 40, 62).”
BackgroundResult
Research works printed but not linked: 1
- Pfaller, M. A., and D. J. Diekema. 2007. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J. Invasive Fungal Infect. 1 : 74-92.
Cited by
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationAzole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“In particular, patients with hematologic malignancies and bone marrow transplants have been shown to be at increased risk of C. krusei infection (Merz et al., 1986; Wingard et al., 1991; Pfaller et al., 2008).”
BackgroundPfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
“We have shown variable cross-resistance between fluconazole and voriconazole when tested against the common species of Candida causing IC [53, 63, 64].”
BackgroundMethodSelf-citationEmerging opportunistic yeast infections
Miceli, M. H., Díaz, J. A., & Lee, S. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70218-8 · Cited by 811
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A.
- Affiliations
- Departments of Pathology
- University of Iowa (US)
- Giles Scientific, Inc., Santa Barbara, California
- Women's and Children's Hospital (AU)
- University of Turin (IT)
- Leipzig University (DE)
- Husa Shan Hospital, Shanghai, China
- Singapore General Hospital (SG)
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2010-04
- Volume
- 48
- Issue
- 4
- Pages
- 1366-1377
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC2849609
- OpenAlex
- W2122716163
- Cited by
- 718
- References
- 75
- Citations by year
- 2026: 27 · 2025: 30 · 2024: 33 · 2023: 40 · 2022: 44 · 2021: 41 · 2020: 40 · 2019: 49 · 2018: 56 · 2017: 56 · 2016: 36 · 2015: 39 · 2014: 57 · 2013: 37 · 2012: 46
- FWCI
- 31.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida, antifungal resistance, fluconazole resistance, voriconazole resistance, Candida glabrata, Candida tropicalis, Candida parapsilosis, Candida guilliermondii, Candida inconspicua, Candida rugosa, Yarrowia lipolytica, Candida pelliculosa, Candida krusei, Candida albicans, non-albicans Candida, emerging fungal pathogens
- MeSH terms
- Antifungal Agents, Candida, Candidiasis, Humans, Microbial Sensitivity Tests, Pyrimidines, Triazoles, Fluconazole, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.